Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

5.815 +0.075 (+1.31%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Valneva (VALN) Q2 2026 Earnings Call Transcript ↗
Restructuring efforts and Lyme vaccine regulatory timeline take center stage. 
Via The Motley Fool
Topics Earnings
News headline image
Valneva Q2 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and... 
Via MarketBeat
Topics Earnings
Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact ↗
Via Stocktwits
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Valneva's Quarterly Earnings ↗
 
Via Benzinga
News headline image
4 Analysts Have This To Say About Valneva ↗
 
Via Benzinga
News headline image
Valneva Q1 Earnings Call Highlights ↗
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme... 
Via MarketBeat
Topics Earnings
News headline image
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July ↗
 
Via Benzinga
Topics Economy
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday ↗
 
Via Benzinga
News headline image
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US ↗
Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 ↗
Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026. 
Via Benzinga
News headline image
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events ↗
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment. 
Via Benzinga
Topics Death
News headline image
12 Analysts Assess Valneva: What You Need To Know ↗
 
Via Benzinga
News headline image
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine ↗
Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions. 
Via Benzinga
News headline image
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Breaking Down Valneva: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot ↗
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions. 
Via Benzinga
News headline image
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults ↗
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.